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Short title: thyroxine and beta amyloid efflux from CSF 
 
ABSTRACT 
Transthyretin (TTR) is a binding protein for the thyroid hormone thyroxine (T4), retinol and 
β-amyloid peptide. TTR aids the transfer of T4 from the blood to the cerebrospinal fluid (CSF), but 
also prevents T4 loss from the blood-CSF barrier. It is however, unclear whether TTR affects the 
clearance of β-amyloid from the CSF. This study aimed to investigate roles of TTR in β-amyloid and 
T4 efflux from the CSF. 
Eight weeks old 129sv male mice were anaesthetized and their lateral ventricles were 
cannulated. Mice were infused with artificial CSF containing 125I-T4 / 3H-mannitol, or 125I-Aβ40 / 3H-
inulin, in present or absent of TTR. Mice were decapitated at 2, 4, 8, 16, 24 minutes after injection. 
The whole brain was then removed and divided into different regions. The radioactivities in the 
brain were determined by liquid scintillation counting.  
At baseline, the net uptake of 125I-T4 into the brain was significantly higher than that of 125I-
Aβ40, and the half time for efflux was shorter (125I-T4: 5.16, 3H-mannitol: 7.44; 125I-Aβ40: 8.34, 3H-
inulin: 10.78; mins). The presence of TTR increased the half time for efflux of 125I-T4 efflux, and 
caused a noticeable increase in the uptake of 125I-T4 and 125I-Aβ40 in the choroid plexus, whilst 
uptakes of 3H-mannitol and 3H-inulin remained similar to control experiments. 
This study indicates that thyroxine and amyloid peptide effuse from the CSF using different 
transporters. TTR binds to thyroxine and amyloid peptide to prevent the loss of thyroxine from the 
brain and redistribute amyloid peptide to the choroid plexus.  
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1. INTRODUCTION 
Transthyretin (TTR), a highly conserved tetrameric protein of 55 kDa, is synthesized mainly in the 
liver in the system and is also present in the choroid plexus (CP) and retina and in the cytoplasm of 
ependymal cells of brain ventricles [1]. The CP contains 10 times more TTR mRNA in per gram of 
tissue than liver and secretes TTR at rate 13 times greater than liver [2]. TTR production accounts for 
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at least 20% of all protein synthesised by the CPs in the rat, and contributes approximately 50% of 
all secreted proteins into the cerebrospinal fluid (CSF) [3,4]. About 6% of total protein in CSF is TTR 
(~15 μg TTR mL-1 of CSF), which binds 80% of T4 in the CSF [5].  
 
The secretion of TTR by the CP into CSF has been suggested to play a key role in the transfer of T4 
from the blood to the CSF, as a unidirectional secretion of TTR to the CSF may drive thyroxin 
hormones (TH) across the blood-CSF barrier (BCB) [6]. In humans, TTR transports about 15% of 
plasma T4, and the rest of T4 are carried with other TH distributing proteins, e.g. thyroxine binding 
proteins (TBG), albumin [7]. In TTR knockout (KO) mice, TTR absence does not impair TH tissue 
contents, despite the low circulating levels of total T4 [8,9]. These observations are in agreement 
with the free hormone hypothesis, that the hormone biological activity depends only on its free 
plasma concentration [10]. In the CSF, TTR is a major T4 carrier [5]. It was reported that T4 
distribution from the CSF into the brain is TTR-dependent and occurs via receptor-mediated 
endocytosis [11,12]. The TTR-T4 interaction poses a preferential relevance in the brain than in the 
peripheral circulation, given there are two other T4 transporter proteins besides TTR being present 
in plasma with TBG having the highest affinity for T4, whereas TTR is the major carrier for T4 in the 
CSF. 
 
Besides being the carrier of T4 and retinol, TTR has been suggested to bind β-amyloid peptide (Aβ) 
essentially protecting the brain from neurotoxic accumulations called amyloid plaques, a hallmark of 
Alzheimer’s disease (AD) [13-16]. TTR binds to both Aβ monomers and oligomers, but preferentially 
binds to the latter [17]. TTR suppressed Aβ aggregation in vitro via an interaction between the 
thyroxine binding pocket of the TTR and Aβ residues 18-21 [14], and prevents its toxicity [18]. In rat 
CP epithelial cell culture experiments, TTR was found to sequester Aβ in the CSF and guided Aβ to 
the CP for enzymatic degradation and removal [19, 20]. TTR is suggested as a protease with 
apolipoprotein A-I (apoA-I) and Aβ as substrates [21]. TTR cleaves Aβ in multiple positions with 
some of the generated Aβ peptides displaying lower amyloidogenic potential than the full-length 
counterpart [18]. As TTR was able to degrade aggregated forms of Aβ, it may contribute not only to 
the maintenance of Aβ levels within a normal range, but also to the removal of deposited Aβ in case 
of imbalance and disease.   
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TTR-Aβ interaction seems to have a neuroprotective effect in AD patients. TTR levels in the brains of 
AD patients are negatively correlated with the abundance of amyloid plaques [22], and TTR is 
upregulated in response to elevated Aβ levels in transgenic mice overexpessing mutant amyloid 
precursor protein [23]. Significant reduction of TTR concentration in CSF of AD patients, compared 
to normal age controls was found by a number of studies [24-27], suggesting the AD patients either 
having reduced TTR production or depleting TTR with enhanced level of Aβ in the brain. While 
Schultz et al. [28] did not find significant changes in TTR in CSF between AD patients and normal 
controls, but found a significant reduction in CSF TTR (14%) in AD patients who were medicated with 
cholinesterase inhibitors compared to those AD patients who were not. 
 
This study was to characterize roles of TTR on β-amyloid clearance from CSF in comparison to 
thyroxine (T4) using an in situ mouse brain perfusion technique, and unravel mechanism of both T4 
and Aβ efflux in a physiology model. 
 
2. RESULTS 
 
2.1. Baseline distribution of 125I-T4 / 125I-Aβ40 in the brain 
 
At baseline, levels of both 125I-T4 and 125I-Aβ40 in the brain were significantly higher than their size matched 
extracellular markers (mannitol and inulin), suggesting active uptakes of T4 and Aβ40 (Fig 1A, Fig 2A). 
Regionally, net levels of 125I-T4 and 125I-Aβ40 in the CP, EP, were higher than those in FX and CB, presumably 
the latter tissues were further away from the injection site – the lateral ventricles (Fig 3,4).  
 
2.2. Efflux half time of 125I-T4 / 125I-Aβ40  
Levels of 125I-T4, 125I-Aβ40 as well as the extracellular makers fell over time in whole brain and in the CSF 
secreting CP (Fig 1,2). These generated linear relation curves, by which the half time for efflux was 
calculated as in the Table 1. Table 1 showed the efflux half time of both 125I-T4 and 125I-Aβ40 were shorter 
than their size matched extracellular markers (mannitol and inulin), suggesting specific transporters for 125I-
T4 and 125I-Aβ40. 
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2.3. Effects of TTR on 125I-T4 / 125I-Aβ40 in the brain 
 
In presence of TTR, levels of 125I-T4 fell over the time but at slower slopes, leading to significant prolonged 
half time of 125I-T4 efflux in brain parenchyma (Fig 1, Table 1). However, TTR did not significantly change the 
125I-Aβ40 efflux half time in brain parenchyma (Fig 2, Table 1). There was a noticeable increase in the uptake 
of 125I-T4 and 125I-Aβ40 in the CP in presence of TTR compared to the baseline, whilst uptakes of 3H-mannitol 
and 3H-inulin remained similar to control experiments (Fig 3,4). TTR had no significant effect on the 
integrities of 125I-Aβ40, as the percentage of loss of 125I activity (cpm in supernatant) were almost equal in 
treatment groups (41.3±4.5% and 42.7±5% in TTR 50, 200 μg.ml-1 respectively, versus 41.5±6.3% in control 
group, p>0.05). 
 
3. DISCUSSION 
 
This study investigated the effect of TTR on T4 and amyloid efflux from the CSF. At baseline (without TTR), 
both 125I-T4 (775 Da) and 125I-Aβ40 (4455 Da) were cleared from brain faster than their corresponding 
extracellular markers, 3H-mannitol (182 Da) and 3H-inulin (5000 Da), consistent with the concept of specific 
transporters for 125I-T4 and 125I-Aβ40, in addition to the diffusion and fluid drainage pathways accessible by 
mannitol and inulin. With TTR in aCSF, the loss of thyroxin from the brain was significantly reduced (i.e. 
efflux half time was prolonged), while the retention of Aβ40 in the brain was not significantly affected (i.e. 
efflux half time was not changed). In presence of TTR, the accumulation of both 125I- T4 and 125I-Aβ40 in the 
CP were significantly increased. Since the nascent CSF is washed out from the ventricular system during 
perfusion with artificial CSF in the experiments, the CSF endogenous TTR approaches zero in these mice 
during the perfusion. 
 
TTR is a protein that binds and distributes the TH in the body. In the blood, >99% of TH is bound to specific 
plasma proteins known as TH distributor proteins, such as TBG, TTR, albumin and ApoB100 [7]. These TH 
binding proteins maintain the large extrathyroidal pool of TH which can be liberated with great rapidity for 
entry into cells, ensure a constant supply of TH to the cells and tissues [1, 7]. In the CSF, TTR assumes the 
main role  in terms of TH homeostasis, as TTR has higher affinity to T4 than the albumin (ca 5-9 x 10-8M vs ca 
7 x 10-5M) [1]. We showed here that TTR affected T4 distribution in the brain and prevented the T4 loss from 
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the brain. The increased accumulation of T4 in the CP by TTR may be due to reduced basolateral efflux (from 
choroid epithelial cells to plasma) as well as an augmented uptake of T4 from CSF. The T4 efflux from the CSF 
involves a number of transporters [29] and is saturable in presence of unlabelled T4 [9, 11, 30]. Despite the 
important role of TTR in TH homeostasis, mice lacking the TTR gene maintain normal functioning of thyroid 
glands in the face of significant reduction in total serum T4 concentration [9]. Using the same model it was 
found that TTR was not essential for TH to reach the brain [8]. This is not surprise given there are numerous 
mechanisms for T4 transport, and a number of thyroxine binding proteins may take over the role of TTR in 
TTR-null mice. Despite the apparent normal distribution of T4 in the brain, TTR knock-out mice have 
behavioural changes, which are associated with an apparent increase of noradrenaline in the limbic 
forebrain of the mice [31, 32].  
 
It has been suggested that TTR has other important physiological effects. TTR could bind Aβ and prevent 
amyloid formation, and also inhibit Aβ induced cytotoxicity [13, 14, 18].  
Aβ deposition in the brain has been linked to the AD pathogenesis. The accumulation of Aβ in the AD brain 
is suggested to be related to defective Aβ clearance from the brain rather than increased Aβ production 
[33]. P-gp and low-density lipoprotein receptor-related protein-1 (LRP-1) in cerebrovasculature have been 
reported to play important roles in Aβ clearance from the brain to the blood [34]. A recent study 
demonstrated that TTR interacted with Aβ directly and stimulated brain-to-blood but not blood-to-brain Aβ 
permeability in hCMEC/D3, a human cerebral microvascular endothelial cell line [35]. Together with one of 
their previous studies [36], they conclude that TTR acts as an Aβ carrier that transports the peptide to its 
receptor both at blood brain barriers in the brain and at the liver in the peripheral system [35, 36]. In our 
study, we intended to use TTR concentrations close to the physiology level in mouse CSF (20-50 μg/ml) [37], 
which are more than that of 125I –Aβ40. The TTR dose effect was not seen. Thus, we could use one dose of 
TTR (i.e.50 μg/ml) in the study. That will be close to the clinical setting. At physiological condition in human, 
TTR is abundant (5-20 μg/ml or 0.1-0.36 μM) [38] while Aβ concentration in CSF is relatively low (3nM or 
less) [39, 40]. The effects of TTR on Aβ neurotoxicity have also been demonstrated in in vivo experiments. 
The silencing the endogenous TTR gene accelerated the appearance of Aβ associated neuropathology, 
while genetically programmed overexpression of a human TTR transgene suppressed both the 
neuropathologic and behavioural abnormalities in the APP23 transgenic mouse model [41]. Backcrossing of 
the TTR null mice with an AD mouse model resulted in an increase in the deposition of Aβ in the brains of 
mice with the hemizygous deletion of TTR [42]. TTR concentration in the CSF was found to negatively 
correlate with AD patients [43], as well as the degree of dementia in patients with AD [44]. However, TTR 
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was not found to change in AD patients compared to age-matched controls in a number of larger AD clinical 
studies such as ADNI (The Alzheimer's disease neuroimaging initiative) [28, 45].  
 
As a main tissue in the brain to secrete CSF and synthesize TTR, the CP is suggested to be a major site of Aβ 
removal in the brain. In a triple transgenic mouse model of AD, CP dysfunction was shown linking to 
increasing Aβ burden resulting in reduced production of CSF and diminished secretion of TTR [46]. In AD 
patients, CSF turnover / clearance is decreased by 50% [47]. It will decrease Aβ40 clearance from the brain 
and increase the contact time for proteins with glucose in the CSF, which promotes the glycosylation of CSF 
proteins and increased oxidative stress [48]. The CP also contains high levels of Aβ degrading enzymes, such 
as neprilysin, endothelin-converting enzyme-1, insulin degrading enzyme [19], which degrade β-amyloid 
peptides. In our study we showed TTR bound to Aβ40 and distributed Aβ40 to the CP, as the CP has high 
affinity to TTR due to presence of TTR receptor [49]. We found significant loss of the integrity of 125I-Aβ / 
TTR complex in the brain tissue detected by the TCA precipitation assay. The loss of radioisotope activity in 
the precipitate could be due to involvement of enzymatic degradation in the CP, blood brain barrier or 
brain parenchyma. The accumulation / degradation of Aβ40 in the CP enhance Aβ40 removal which is 
known to occur at the CPs via receptor mediated processes [e.g. via the LRP1] that are modulated by 
chaperone complexes such as ApoE,  clusterin, TTR [50]. In the CP, the abundance of LRP-1 increases with 
age, whereas the abundance of LRP-2 (megalin) is reduced during normal ageing in rodent [51]. Megalin is 
thought to contribute to the clearance of Aβ through the CP [52], and patients with AD have reduced levels 
of megalin at the CP [53]. Since the BBB is not intact with the clearance deficits in the AD patients, the role 
of Aβ transport and degradation at the CP becomes increasingly more prominent and needs further 
investigating.  
 
In conclusion, this study demonstrates that TTR acts differentially on T4 and Aβ40 efflux from the CSF. TTR 
prevents the loss of thyroxine from the CSF, a positive adaptation since T4 is a substrate for multiple efflux 
transporters from the CSF, but is a necessary requirement for normal brain function. TTR does not 
significantly affect the retention of Aβ40 in the brain parenchyma, but redistributes Aβ40 to the CP for 
degradation and clearance. As a major site of TTR synthesis in the brain, the CP is an important site for 
homeostasis of TTR binding hormone and peptides.  
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4. METHODS 
 
4.1. Mouse lateral ventricular perfusion 
 
All procedures were within the guidelines of the Animals (Scientific procedures) Act, UK, 1986. Eight 
week old C57/BL6 male mice (20-25g) were ordered from Harlan (UK) and were kept on a 12-h 
light/dark cycle with food and water freely available. They were anaesthetized with i.p. 0.1 ml 
Vetalar (100mg.ml-1 ketamine anaesthetic) and 0.2 ml Domitor (1mg.ml-1 medetomidine 
analgesic/sedative) and injected with heparin (1000 U.Kg-1). The mice were put on a stereotaxic 
frame, the scalp removed and a hole made in the skull above each lateral ventricle, 1.0 mm lateral 
and 1.0 mm posterior to the bregma. A 33 gauge needle was used to make the hole, and had a 
tubing guard which kept the depth of the holes constant (2.5 mm).   
 
A syringe driver contained artificial CSF (aCSF) (NaCl: 6.821; KCl: 0.2238; MgCl2 6H2O: 0.1626; 
Na2HPO4: 0.0994; NaHCO3: 1.512; Urea: 0.1202; Glucose: 2.178; CaCl24H2O: 0.2058; g.L-1) with either 
125I-T4 (0.037 MBq.ml-1; 8.62 nM) plus 3H-mannitol (0.148 MBq.ml-1; 26.47 μM) or 125I-Aβ40 (0.09 
MBq.ml-1; 1.1 nM) plus 3H inulin (0.37 MBq.ml-1; 15.4 μM) was run at 1μl.min-1 for 1 min at either 
absence or presence of TTR (50 or 200 μg.ml-1). Aβ40 was studied in this study, as it is several folds 
higher than Aβ42 in the brain and its accumulation disrupts the integrity of BBB [54], although Aβ40 
is less pathogenic than Aβ42 due to its low propensity to aggregate [55]. The radio-labelled mannitol 
(182 Da) and inulin (5000 Da) acted as size-matched, non-transported, extracellular markers for 125I-
T4 (775 Da) and 125I-Aβ40 (4455 Da) respectively. Radio-isotopes were purchased from GE Life 
Sciences (Buckinghamshire, England) and Perkin-Elmer (Boston, USA).  
 
Human TTR (huTTR) was obtained from Biodesign International (Maine, USA) and dissolved in saline. 
100 μl of either 125I-T4 (0.037 MBq.ml-1; 8.62 nM) or 125I-Aβ40 (0.09 MBq.ml-1; 1.1 nM) was mixed 
with 1 ml of TTR (50 / 200 μg.ml-1; 0.909/3.636 μM). The mixture was allowed to bind for 30 min at 
room temperature and was then dialyzed overnight at 4 °C in seamless cellulose tubing (with a 
cutoff of 12kD mol wet) (St. Louis, MO, USA) to remove any unbound T4 or Aβ40.  
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4.2. Sampling of the brain tissue, TCA precipitation and radioactive counting 
 
At 2, 4, 8, 16, 24 minutes after the injection, the mice were killed with overdose sodium 
pentobarbital. The heart was exposed and blood taken using a syringe inserted in the left ventricle. 
The brain was then washed with cold PBS and was dissected into right and left frontal cortex (FX), 
choroid plexus (CP), ependymal lining lateral ventricles (EP), hippocampus (HC), cerebellum (CB) and 
rest of brain (ROB). Samples were weighed on a Cahn microbalance (Thermo, USA), and 
homogenized with PBS in a glass homogenizer. 
 
The TCA precipitation method was used to determine how much 125I was still attached to Aβ at the 
end of the experiments [56]. To measure intact 125I-Aβ, one volume of TCA (20%) was added to the 
sample, and then samples were vortexed, incubated in ice for 30 min and centrifuged at 14,000 rpm 
at 4 °C for 30 min. Following centrifugation, radioactivity of precipitated 125I-Aβ40 (intact peptide) 
and TCA supernatant (degraded peptide) were measured on a LKB Rackbeta liquid scintillation 
counter (Wallac). Solvables (National Diagnostic, UK) was added to each of samples to dissolve 
organic samples overnight. The radioactivities of the tissues and 100μl of infused aCSF were 
determined by liquid scintillation counting (LKB Wallac Rackbeta Spectral 1219 counter) after the 
addition of 3.0 ml liquid scintillation fluid (Ultima Gold, Packard Bioscience, Netherland).   
 
4.3. Expression of results 
 
Regional brain uptake (volume of distribution) was calculated using equation: 
 
Vd (ml.g-1) = 100*(Tissue dpm.g-1) / (aCSF dpm.ml-1)    (1) 
 
The half-time for efflux of 125I-T4 and 125I-Aβ40 from brain was calculated according to Banks et al 
[57]. Briefly, LogVd was plotted against time and the slope of the line was calculated where: 
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Efflux half time (min) = Log2 / slope of line     (2) 
  
4.4. Data analysis 
 
All values were expressed as mean SEM. ANOVA and unpaired t-test as appropriate were used to 
compare means. Values of p<0.05 were considered statistically significant. 
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FIGURE LEGENDS 
 
Figure 1. 125I-T4 efflux after lateral ventricle injection. Levels of 125I-T4 and its size matched extracellular 
marker 3H-mannitol fell over time in whole brain. 125I-T4 was cleared faster than 3H-mannitol at the baseline 
(A). The addition of TTR (B: 50 μg.ml-1; C: 200 μg.ml-1) slowed the 125I-T4 clearance but did not affected 3H 
mannitol one. Solid squares are 125I-T4 LogVd while open squares represent 3H-mannitol LogVd. Values are 
mean ± SEM, n=3-5. 
 
Figure 2. 125I-Aβ40 efflux after lateral ventricle injection. Levels of 125I-Aβ40 and its size matched 
extracellular marker 3H-inulin fell over time in whole brain. 125I-Aβ40 was cleared faster than 3H-inulin at the 
baseline (A). The addition of TTR (B: 50 μg.ml-1; C: 200 μg.ml-1) did not affect the 125I-Aβ40 and 3H-inulin 
clearance (B, C). Solid circles are 125I-Aβ40 LogVd, while open circles represent 3H-inulin LogVd. Values are 
mean ± SEM, n=3-5. 
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Figure 3. Regional brain uptake of 125I-T4 at 16min post lateral ventricle injection. Baseline uptake of 125I-T4 
showed highest accumulation in the CP (choroid plexus). The ependymal ventricular lining (EP) also showed 
some uptake of 125I-T4, however, the rest of brain did not show much uptake. The addition of TTR to the 
lateral ventricles resulted in increased retention of 125I-T4 in the CP, and the increase reached significance 
with TTR 200 μg.ml-1. 
The addition of TTR did not change retention of 125I-T4 in EP, HC, FX and CB. HC = hippocampus, FX = front 
cortex, CB = cerebellum. Values are mean ± SEM, n=3-5. * means p<0.05 compared to baseline. 
 
Figure 4. Regional brain uptake of 125I-Aβ40 at 16min post lateral ventricle injection. Baseline uptake of 125I-
Aβ40 showed highest accumulation in the CP (choroid plexus). Brain parenchymal uptake was lower, and 
only the ependymal ventricular lining (EP) showed some uptake of 125I-Aβ40. The addition of TTR to the 
lateral ventricles resulted in significant increased retention of 125I-Aβ40 in the CP, but did not change 
retention of 125I -Aβ40 in EP, HC, FX and CB. HC = hippocampus, FX = front cortex, CB = cerebellum. Values 
are mean ± SEM, n=3-5. * means p<0.05 compared to baseline. 
 
 
Table 1. Efflux half time of 125I-T4, 125I-Aβ and the extracellular markers 3H-mannitol, 3H-
inulin in whole mouse brain in absence and presence of TTR 
 
Efflux half time (min) 
in whole brain 
125I-T4 3H-mannitol 125I-Aβ 3H-inulin 
Baseline (n=5) 5.16 ± 0.27 7.44 ± 0.26 8.34 ± 0.39 10.78 ± 0.7 
TTR 50 μg.ml-1 (n=4) 7.88 ± 0.35* 7.74 ± 0.25 9.04 ± 0.17 11.32 ± 0.62 
TTR 200 μg.ml-1 (n=3) 7.97 ± 0.31* 7.92 ± 0.40 9.23 ± 0.22 10.68 ± 0.80 
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